Validation of Prognostic Marker Tests: Statistical Lessons Learned From Regulatory Experience

Therapeutic Innovation & Regulatory Science
Rong Tang, Gene Pennello

Abstract

Despite concerted efforts to discover and validate prognostic biomarkers or signatures, few medical tests indicated for prognostic uses have been widely accepted by the clinical community. Even fewer, perhaps, are covered by public or private health plans. We were able to identify 6 prognostic marker tests that have been approved or cleared by the US Food and Drug Administration. The pivotal clinical studies for these prognostic marker tests exhibited a wide variety of designs and statistical analyses. From these experiences, we develop statistical points to consider for design, conduct, and analysis of successful clinical validation studies of prognostic tests. In particular, we review broad themes regarding prospective and retrospective study designs, sample size, clinical performance evaluation, and handling of missing data. Our review emphasizes the distinction between a prognostic biomarker and the medical test used to measure it. For this purpose, a section on test measurement validation is also provided.

References

May 1, 1992·American Journal of Epidemiology·S WacholderJ S Mandel
May 1, 1992·American Journal of Epidemiology·S WacholderJ S Mandel
May 1, 1992·American Journal of Epidemiology·S WacholderJ S Mandel
Feb 6, 1991·Journal of the National Cancer Institute·W L McGuire
Jun 1, 1994·British Journal of Cancer·R Simon, D G Altman
Dec 1, 1996·Journal of Clinical Epidemiology·P PeduzziA R Feinstein
Dec 2, 1999·Journal of Clinical Epidemiology·W E BarlowS Izumi
Mar 1, 2000·Statistics in Medicine·D G Altman, P Royston
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H YamauchiD F Hayes
May 2, 2002·Proceedings of the National Academy of Sciences of the United States of America·Christophe Ambroise, Geoffrey J McLachlan
Jan 2, 2003·Journal of the National Cancer Institute·Richard SimonLisa M McShane
Feb 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael W Kattan
Apr 24, 2004·American Journal of Epidemiology·Margaret Sullivan PepePolly Newcomb
Aug 20, 2004·The New England Journal of Medicine·Massimo CristofanilliDaniel F Hayes
Mar 18, 2005·Biostatistics·Mitchell H Gail, Ruth M Pfeiffer
Sep 7, 2006·Journal of the National Cancer Institute·Marc BuyseUNKNOWN TRANSBIG Consortium
Sep 19, 2006·Journal of Clinical Epidemiology·Karel G M MoonsFrank E Harrell
Dec 22, 2006·American Journal of Epidemiology·Eric Vittinghoff, Charles E McCulloch
Dec 22, 2006·The New England Journal of Medicine·James H Ware
Jan 24, 2007·American Heart Journal·David J WhellanUNKNOWN HF-ACTION Trial Investigators
Apr 7, 2007·Journal of the American College of Radiology : JACR·Jennifer A Henderson, John J Smith
Nov 6, 2007·American Journal of Epidemiology·Margaret S PepeYingye Zheng
Oct 9, 2008·Journal of the National Cancer Institute·Margaret S PepeJohn D Potter
Feb 25, 2009·BMJ : British Medical Journal·Karel G M MoonsDouglas G Altman
Apr 15, 2009·Circulation·Mark A HlatkyUNKNOWN American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Cou
Dec 1, 2007·Molecular Oncology·Fatima CardosoUNKNOWN TRANSBIG Consortium
May 30, 2009·BMJ : British Medical Journal·Douglas G AltmanKarel G M Moons
Jun 9, 2009·BMJ : British Medical Journal·Karel G M MoonsPatrick Royston
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sumithra J Mandrekar, Daniel J Sargent
Jan 1, 2008·Journal of the American Statistical Association·Yingye ZhengWayne C Levy
Oct 10, 2009·Journal of the National Cancer Institute·Richard M SimonDaniel F Hayes
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F Ransohoff, Margaret L Gourlay
Apr 28, 2010·Nature Reviews. Clinical Oncology·Jyothi Subramanian, Richard Simon
Nov 9, 2010·Nature Biotechnology·Kevin A Schulman, Sean R Tunis
Dec 16, 2010·Biometrics·R M Pfeiffer, M H Gail
Mar 11, 2011·Journal of Biopharmaceutical Statistics·Gregory CampbellLilly Yue
Mar 17, 2011·Expert Review of Molecular Diagnostics·Marc BuyseAimery de Gramont
Aug 23, 2011·Biostatistics·Tianxi Cai, Yingye Zheng

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay

Software Mentioned

ProsVue
CellSearch
MammaPrint

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Special Operations Medicine : a Peer Reviewed Journal for SOF Medical Professionals
John F KraghElizabeth A Mann-Salinas
Journal of the National Cancer Institute
Miguel R OssandonJames V Tricoli
© 2022 Meta ULC. All rights reserved